A5018252129- Cancer-related molecular mechanisms research
- RNA regulation and disease
- RNA Research and Splicing
- Protein Degradation and Inhibitors
- Cutaneous Melanoma Detection and Management
- CRISPR and Genetic Engineering
- Circular RNAs in diseases
- Allergic Rhinitis and Sensitization
- Inhalation and Respiratory Drug Delivery
- Cancer therapeutics and mechanisms
- Advanced Biosensing Techniques and Applications
- Neuroblastoma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- melanin and skin pigmentation
- Beetle Biology and Toxicology Studies
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
University of California, San Francisco
2019-2024
Cancer Research Center
2019-2024
Rudolfinerhaus Hospital
2013-2019
Activating mutations in the neuroblastoma rat sarcoma viral oncogene homolog (NRAS) gene are common genetic events malignant melanoma being found 15–25% of cases. NRAS is thought to activate both mitogen activated protein kinase (MAPK) and PI3K signaling cells. We studied influence different components on MAP/extracellular signal-regulated (ERK) (MEK) PI3K/mammalian target rapamycin (mTOR)-signaling cascade mutant In general, these cells were more sensitive MEK inhibition compared with...
Abstract Finding effective therapeutic targets to treat NRAS-mutated melanoma remains a challenge. Long non-coding RNAs (lncRNAs) recently emerged as essential regulators of tumorigenesis. Using discovery approach combining experimental models and unbiased computational analysis complemented by validation in patient biospecimens, we identified nuclear-enriched lncRNA ( AC004540.4 ) that is upregulated NRAS/MAPK-dependent melanoma, named T-RECS . Considering potential innovative treatment...
The long non-coding RNA (lncRNA) MALAT1 is a regulator of oncogenesis and cancer progression. MAPK-pathway upregulation the main event in development progression human cancer, including melanoma recent studies have shown that has significant impact on regulation gene protein expression MAPK pathway. However, role kinases RAS, RAF, MEK ERK largely unknown. We demonstrate impacts antisense oligonucleotide (ASO)-based MALAT1-inhibition melanoma. Our results showed MALAT1-ASO treatment decreased...
Interleukin-2 (IL-2) treatment for patients with metastatic melanoma has shown remarkable durable responses. Systemic administration of IL-2 may cause severe side effects, whereas local is considered to be a safe alternative. The lungs are common sites metastases in causing considerable respiratory problems. We sought evaluate the potential antitumoral effect low-dose inhalative (lh-IL-2) regimen lung metastases. In addition, we explored prophylactic Ih-IL-2 after surgical removal study...
// Igor Vujic 1,2 , Christian Posch Martina Sanlorenzo 1,3 Adam J. Yen 1 Aaron Tsumura Andrew Kwong Valentin Feichtenschlager 2 Kevin Lai Douglas V. Arneson Klemens Rappersberger and Susana M. Ortiz-Urda University of California San Francisco, Mt. Zion Cancer Research Center, USA Rudolfstiftung Hospital, Academic Teaching Medical Vienna, Department Dermatology, Juchgasse, Austria 3 Sciences, Section Turin, Italy Correspondence: Vujic, email: Keywords : NRAS, combination therapy, lung cancer,...
Abstract MAPK-pathway up-regulation is responsible for over 40% of human cancer cases. Finding effective therapeutic targets melanoma therapy continues to be a challenge due drug resistance. Using computational and experimental pipeline, we discovered the nuclear enriched long non-coding RNA (lncRNA) TRASH, which induced upon MAPK-pathway-activation in melanoma. LncRNA hold essential regulatory functions many types. TRASH-targeting Antisense Oligonucleotides (TRASH-ASOs) greatly reduced...
Abstract Finding effective therapeutic targets to treat NRAS-mutated melanoma remains a challenge. Long non-coding RNAs (lncRNAs) recently emerged as essential regulators of tumorigenesis. Using discovery approach combining experimental models and unbiased computational analysis complemented by validation in patient biospecimens, we identified nuclear-enriched lncRNA ( AC004540.4 ) that is upregulated NRAS/MAPK-dependent melanoma, named T-RECS . Considering potential innovative treatment...
Abstract Finding effective therapeutic targets to treat NRAS-mutated melanoma remains a challenge. Long non-coding RNAs (lncRNAs) recently emerged as essential regulators of tumorigenesis. Using discovery approach combining experimental models and unbiased computational analysis complemented by validation in patient biospecimens, we identified nuclear-enriched lncRNA ( AC004540.4 ) that is upregulated NRAS/MAPK-dependent melanoma, named T-RECS . Considering potential innovative treatment...